Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16007827 | 1.00 | NTMT1 (0.59) | NTMT1UGCG | |
| Hydrochloric Acid SCHEMBL17504473 | 0.99 | NTMT1 (0.58) | NTMT1UGCG | |
| Malic Acid SCHEMBL17504472 | 0.91 | NTMT1 (0.52) | NTMT1UGCG | |
| Malic Acid SCHEMBL17504470 | 0.91 | NTMT1 (0.52) | NTMT1UGCG | |
| SCHEMBL16933476 | 0.84 | NTMT1 (0.49) | NTMT1UGCG | |
| SCHEMBL16933647 | 0.83 | NTMT1 (0.49) | NTMT1UGCG | |
| SCHEMBL17504471 | 0.82 | NTMT1 (0.50) | NTMT1UGCG | |
| SCHEMBL20687127 | 0.78 | NTMT1 (0.75) | NTMT1UGCG | |
| SCHEMBL16933488 | 0.78 | NTMT1 (0.46) | NTMT1UGCG | |
| SCHEMBL16933646 | 0.77 | NTMT1 (0.46) | NTMT1UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857512-B2 | Pharmaceutical compositions comprising venglustat | GENZYME CORPORATION (US) | 2024-01-02 | — | — | US | claimed |
| WO-2021067243-A1 | TREHALOSE FORMULATIONS AND USES THEREOF | SEELOS THERAPEUTICS, INC. (US) | 2021-04-08 | — | — | WO | claimed |
| US-20160039805-A1 | SALT FORMS OF (S)-QUINUCLIDIN-3-YL (2-(2-(4-FLUOROPHENYL)THIAZOL-4-YL)PROPAN-2-YL)CARBAMATE | GENZYME CORPORATION (US) | 2016-02-11 | — | — | US | claimed |
| US-20260021126-A1 | TREHALOSE FORMULATIONS AND USES THEREOF | SEELOS THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12370204-B2 | Trehalose formulations and uses thereof | SEELOS THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-3514157-B1 | METHOD OF PREPARING GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-4188381-A1 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | Genzyme Corporation (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220409595-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-20220387463-A1 | TREHALOSE FORMULATIONS AND USES THEREOF | SEELOS THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| WO-2022024062-A1 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | GENZYME CORPORATION (US) | 2022-02-03 | — | — | WO | disclosed |
| US-20220016092-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GENZYME CORPORATION (US) | 2022-01-20 | — | — | US | disclosed |
| EP-3079695-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20160039805-A1 | SALT FORMS OF (S)-QUINUCLIDIN-3-YL (2-(2-(4-FLUOROPHENYL)THIAZOL-4-YL)PROPAN-2-YL)CARBAMATE | GENZYME CORPORATION (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160039805-A1 | SALT FORMS OF (S)-QUINUCLIDIN-3-YL (2-(2-(4-FLUOROPHENYL)THIAZOL-4-YL)PROPAN-2-YL)CARBAMATE | GENZYME CORPORATION (US) | 2016-02-11 | — | — | US | disclosed |
| US-9139580-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2015-09-22 | — | — | US | disclosed |
| US-9126993-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
| WO-2015089067-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20140371460-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2014-12-18 | — | — | US | disclosed |
| US-20140255381-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NTMT1 795/4885UGCG 4/4885 |
| US-20160039805-A1 | SALT FORMS OF (S)-QUINUCLIDIN-3-YL (2-(2-(4-FLUOROPHENYL)THIAZOL-4-YL)PROPAN-2-YL)CARBAMATE | GBA1, GBA2, GALC | NTMT1 1228/4885UGCG 6/4885 |
| US-20260021126-A1 | TREHALOSE FORMULATIONS AND USES THEREOF | TREH, MAN2B1, GAA | NTMT1 314/4885UGCG 42/4885 |
| US-20220016092-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GAA, GBA1, GALC | NTMT1 2471/4885UGCG 84/4885 |
| US-20220409595-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NTMT1 787/4885UGCG 5/4885 |
| US-20140371460-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NTMT1 814/4885UGCG 4/4885 |
| US-11857512-B2 | Pharmaceutical compositions comprising venglustat | SOST, SLC5A1, SLC10A6 | NTMT1 649/4885UGCG 60/4885 |
| US-20140255381-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NTMT1 814/4885UGCG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.